Compare VOXR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOXR | ABEO |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.5M | 399.5M |
| IPO Year | 2022 | 2005 |
| Metric | VOXR | ABEO |
|---|---|---|
| Price | $5.60 | $5.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.90 | ★ $20.00 |
| AVG Volume (30 Days) | 407.2K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $60.51 | $1,024.31 |
| Revenue Next Year | $44.51 | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $3.44 | $4.00 |
| 52 Week High | $6.70 | $7.65 |
| Indicator | VOXR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 33.09 |
| Support Level | $4.81 | $5.23 |
| Resistance Level | $5.86 | $5.55 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 50.00 | 11.88 |
Vox Royalty Corp is a returns-focused mining royalty and streaming company. It holds a diversified portfolio of several royalties and streams, including producing and development stage assets, with primary exposure to gold and select industrial metals across top-tier mining jurisdictions. Vox is organized into two operating segments, consisting of acquiring and managing royalty interests; and acquiring and managing streams and other interests. Maximum revenue is generated from its Royalty Interests segment. The majority of the company's portfolio of royalty, streams, and other interests by asset count is located in Australia, Canada, and the United States, of which the maximum revenue is derived from its assets in Australia.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.